Oregon Attorney General Dan Rayfield filed a $900 million lawsuit against the nation’s largest insulin manufacturers, ...

The lawsuit alleges three manufacturers coordinated with three pharmacy benefit managers in a scheme to inflate insulin ...

Explore India's urgent need to bridge the healthcare gap for children with Type 1 Diabetes (T1D) by ensuring universal access ...

Insulin is often cited as a prime example of soaring drug costs after years of price hike by drug manufacturers.

The global diabetes injection pens market is projected to grow at a CAGR of approximately 7% through 2028. Market expansion ...

Drugmaker Cipla has launched Afrezza (insulin human) inhalation powder, the company said, about a year after the product got regulatory approval in India. The company has the exclusive distribution ...

Cipla has launched inhaled insulin powder in India, providing a needle-free alternative for diabetes patients. Approved by CDSCO, Afrezza offers a convenient way to manage diabetes, especially for ...

India’s Cipla Limited (BSE: 500087) announced the launch of Afrezza (insulin human) Inhalation Powder in India.

For most healthy women, optimal fasting insulin levels should be less than 25 mIU/L (milli-international units per liter), ...

The insulin inhalation powder in Afrezza is available in single-use cartridges and is delivered via an inhaler device.

The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.

For many of these uses, the scientific backing is far weaker than that for GLP-1 drugs. Yet many users extrapolate from the ...